<DOC>
	<DOCNO>NCT01875341</DOCNO>
	<brief_summary>Hypertension highly prevalent type 2 diabetic patient ( NIDDM ) nephropathy , single important determinant rate renal function loss . In many patient , hypertension resistant therapy . Although increased sympathetic activity also highly prevalent NIDDM patient nephropathy chronic renal insufficiency , little attention pay sleep apnea cause resistant hypertension sympathetic hyperactivity population . Since prevalence sleep apnea increase patient either NIDDM , resistant hypertension , chronic renal insufficiency , almost certain sleep apnea high prevalence patient three state co-exist , i.e . NIDDM patient nephropathy hypertension resistant therapy . As consequence undetected untreated sleep apnea , resistant hypertension , nocturnal hypertension , sympathetic hyperactivity likely contribute accelerate loss renal function increase cardiovascular morbidity mortality patient . Hypothesis : A . Sleep apnea highly prevalent type 2 diabetic patient diabetic nephropathy hypertension resistant therapy . Treatment nasal continuous positive airway pressure ( NCPAP ) result decrease blood pressure restore normal diurnal blood pressure pattern . B . Sleep apnea-caused hypertension mediate sympathetic hyperactivity increase activity renin-angiotensin-aldosterone system ( RAAS ) type 2 diabetic patient nephropathy . A decrease sympathetic hyperactivity response NCPAP therapy result decrease plasma renin activity plasma aldosterone concomitant decrease blood pressure . Randomized , double blind , parallel comparative ( two group ) one center trial . Therapeutic treatment nasal continuous positive airway pressure ( NCPAP ) Sub-therapeutic treatment nasal continuous positive airway pressure</brief_summary>
	<brief_title>Role Sleep Apnea Sympathetic Activity Resistant Hypertensive Patients .</brief_title>
	<detailed_description>The study double blind consist two parallel group . Patients type 2 diabetes creatinine clearance 20 ml/min microalbuminuria proteinuria resistant hypertension sleep apnea study . Creatinine clearance proteinuria assess 24 hour urine collection old 6 month . Microalbuminuria assess least 2 3 positive random urine sample last one old 6 month . Blood pressure consider resistive treatment patient 3 antihypertensive medication blood pressure reading great 140/90 mmHg last 2 3 office visit . Sleep apnea syndrome define presence least 5 apneic hypopneic episode per hour overnight sleep study . Screening do follow manner : Patients see Hypertension Unit University Ottawa Heart Institute , General Nephrology Clinic Progressive Renal Insufficiency Clinic Ottawa Hospital , screen study coordinator . For patient meet study criterion , attend physician ask permission contact patient . If patient agree participate , undergo sleep study . Screening patient subsequent sleep study continue 54 consecutive patient moderate severe sleep apnea ( 15 apneic hypopneic episode per hr ) find enrol study . The prevalence sleep apnea specialty clinic population calculate number patient sleep apnea diagnose base sleep study divide total number clinic patient screen underwent sleep study . After baseline visit completion preliminary procedure , specific study microneurography , plasma renin aldosterone perform . Consequently , 24 hour blood pressure monitor 24 hour urine collection creatinine clearance , microalbuminuria proteinuria do . Once test complete , patient randomize therapeutic sub-therapeutic treatment nasal continuous positive airway pressure 6 week . After 6 week treatment specific study , 24 hour blood pressure monitor 24 hour urine collection repeat .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>. 1 . Males females 18 year old 2 . On 3 antihypertensive medication resistant hypertension &gt; 140/90 mmHg ( rest ) despite treatment 3 . Diagnosis sleep apnea ( 15 apneic/hypopneic episode per hour score 10 Epworth sleepiness scale ) . 4 . Creatinine clearance &gt; 20 ml/min microalbuminuria proteinuria , ( result within past 6 month ) 1 . Acute coronary syndrome within 6 month 2 . Patients clinically document congestive heart failure 3 . Patients relevant cardiac arrhythmia ( second thirddegree heart block premature ventricular complex Lown class IV V ) 4 . Pregnant lactate woman 5 . Patients leg injury involve nerve damage 6 . Patients symptomatic peripheral neuropathy 7 . Patients predominant central sleep apnea 8 . Patients mentally unable give inform consent 9 . Professional driver 10 . Patients rest blood pressure &gt; 180/110 mmHg 11 . Patients take clonidine 12 . Patients sleep apnea cause daily drowsiness 13 . Patients severe hyperkalemia ( &gt; 5.5 mmol/L ) hypokalemia ( &lt; 3.3 mmol/L ) 14 . Patients BMI &gt; 35</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>type 2 diabetes</keyword>
	<keyword>diabetic nephropathy</keyword>
	<keyword>hypertension</keyword>
	<keyword>sleep apnea</keyword>
	<keyword>sympathetic hyperactivity</keyword>
</DOC>